Retension Pharmaceuticals, Inc. has reported a stock option grant to its director, Franklin M. Berger. This move is significant as it reflects the company's strategy to incentivize its leadership and align their interests with those of shareholders.
Retension Pharmaceuticals, Inc., categorized under the SIC code 2834 for Pharmaceutical Preparations, is publicly traded on the Nasdaq under the ticker RTSN. The company is classified as an emerging growth company and is incorporated in Delaware. Its fiscal year ends on December 31.
The filing indicates that on October 8, 2026, Berger was granted stock options to purchase 5,636 shares of common stock at an exercise price of $12.00 per share. The options will vest over time, with 25% becoming available on the first anniversary of the grant date and the remainder vesting in quarterly increments, contingent on Berger’s continued service with the company.
This stock option grant may affect Retension's leadership dynamics and employee morale, as it is designed to retain top talent within the organization. Aligning executive compensation with company performance is a common practice in the pharmaceutical industry, which may influence how competitors structure their own incentive programs.
Details were not available in the SEC filing regarding any future actions or additional filings related to this grant.